Pemvidutide targets fat while protecting your muscle better than any other weight loss drug tested. Phase 2 showed only 21.9% lean mass loss, compared to up to 40% with standard GLP-1 drugs. The best fat-to-muscle ratio in its class.
GLP-1 reduces appetite. Glucagon raises your metabolic rate. Together they direct your body to burn fat preferentially over muscle. One of the least-discussed side effects of GLP-1 drugs is muscle loss. When you lose weight rapidly, through any method, your body doesn't only burn fat. It also breaks down lean tissue, including muscle. With typical GLP-1 drugs, up to 40% of weight lost can come from lean mass. Pemvidutide appears to change that equation significantly.
Source: Altimmune Phase 2 MOMENTUM trial MRI sub-study, 67 subjects. Historical comparisons are from published literature, not direct comparison trials.
A small subcutaneous injection, similar to Wegovy. The dose starts low and increases gradually to minimize side effects. Phase 3 trials will test the optimal dosing regimen for the full population.
The GLP-1 component reduces appetite, food cravings, and the speed of digestion. The glucagon component simultaneously raises your resting metabolic rate. Both effects work together to create a calorie deficit.
The glucagon activation appears to direct your metabolism preferentially toward fat stores, which may explain why lean mass preservation was better than any other weight loss drug tested in Phase 2. This effect was even stronger in older adults, who are more vulnerable to muscle loss.
15.6% weight loss at 48 weeks. Only 21.9% of weight lost was lean mass, better than every other drug in class. The Phase 2 MOMENTUM trial enrolled adults with obesity across 48 weeks at three dose levels (1.2mg, 1.8mg, 2.4mg once weekly). Results were presented at the American Diabetes Association's 84th Scientific Sessions in 2024. The body composition MRI sub-study provided some of the most important data on lean mass preservation ever published for a weight loss drug.
Pemvidutide is also being developed for MASH (metabolic-associated steatohepatitis), a serious liver condition strongly linked to obesity. The Phase 2b IMPACT trial showed significant improvements in liver-related biomarkers at 24 weeks alongside weight loss. A Phase 3 MASH trial is planned for 2026. If both obesity and MASH indications advance to approval, pemvidutide could become one of the most versatile drugs in its class.
End-of-Phase 2 FDA meeting complete. Four Phase 3 VELOCITY trials starting 2025-2026. Altimmune reached a key milestone in November 2024 when it completed its End-of-Phase 2 meeting with the FDA and got agreement on the Phase 3 design. That's the regulatory green light to move forward, and it means the Phase 3 program is clearly defined.
"Dual agonists aren't all the same, the balance between the two targets matters. Pemvidutide's specific formulation is different from tirzepatide's and I think that gets glossed over. Whether that difference shows up clinically is what I'm looking for in the data."
Endocrine Surgeon · GLP-1 Specialist
Especially promising for people who care about body composition, not just the number on the scale. Pemvidutide's headline story is muscle preservation, but it's also a strong weight loss drug in its own right. Here's who stands to benefit most.
The weight loss numbers look similar to some approved drugs, but pemvidutide's differentiator is what the weight loss is made of.
| Drug | Weight Loss | Lean Mass Lost | Form | Status |
|---|---|---|---|---|
| 💉Pemvidutide You're here |
15.6% (Ph2) | 21.9% ✓ Best | Weekly injection | Phase 3 |
| 💉Retatrutide | 24% (Ph2) | Not yet reported | Weekly injection | Phase 3 |
| 💉CagriSema | 22.7% (Ph3) | Not reported | Weekly injection | FDA Review |
| 💉Zepbound | 21% | 25-35% | Weekly injection | ✓ Approved |
| 💉Wegovy | 15% | 35-40% | Weekly injection | ✓ Approved |
Lean mass percentages for approved drugs are from observational studies and are not directly comparable to pemvidutide's controlled MRI sub-study. Phase 2 weight loss data cannot be directly compared to Phase 3 data.